Mp27-14 Feasibility Assessment of Catheter-Free Water Vapor Thermal Therapy for Treatment of Benign Prostatic Hyperplasia

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II (MP27)1 May 2024MP27-14 FEASIBILITY ASSESSMENT OF CATHETER-FREE WATER VAPOR THERMAL THERAPY FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Vi Nguyen, Joshua Winograd, Alia J. Codelia-Anjum, Kevin C. Zorn, Dean Elterman, Naeem Bhojani, Seth K. Bechis, and Bilal Chughtai Vi NguyenVi Nguyen , Joshua WinogradJoshua Winograd , Alia J. Codelia-AnjumAlia J. Codelia-Anjum , Kevin C. ZornKevin C. Zorn , Dean EltermanDean Elterman , Naeem BhojaniNaeem Bhojani , Seth K. BechisSeth K. Bechis , and Bilal ChughtaiBilal Chughtai View All Author Informationhttps://doi.org/10.1097/01.JU.0001009400.86696.a2.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We sought to investigate feasibility of performing water vapor thermal therapy (WVTT; Rezum, Boston Scientific, Marlborough, MA, USA) without postoperative catheterization among men with benign prostatic hyperplasia. METHODS: This is a prospective, single arm, unblinded pilot study of 20 consecutive male patients ages 40-80 who underwent WVTT at a single academic institution. Number of injections received was at discretion of the principal surgeon based upon prostate length. Patients underwent baseline visit 30 days prior to surgery and follow up at 3 days and 1, 3, and 6 months. Primary outcome was evaluation of voiding parameters, symptom scores, and need for catheterization. Voiding parameters and symptom scores were evaluated by paired t-tests and paired Wilcoxon signed-rank tests. RESULTS: Mean age was 65 years (range: 55-75). Mean prostate volume was 43 cc (range: 30-68) with 30% (n=6) having median lobes. Every patient received 2 intraoperative treatments. Only 1 patient (prostate volume 55 cc, no median lobe) required catheterization for acute urinary retention on postoperative day 2. 1 patient endorsed hematuria, which resolved without catheterization or medical intervention. No patients required antibiotic prescription for urinary tract infection or inpatient readmission within 30 days. Qmax significantly increased from a baseline of 6.1 mL/s to 8.3, 12.9, 11.9, and 13.7 at 3 days, 1, 3, and 6 months (p<0.05; Table 1). OAB-SF decreased from 45 to 28, 29, 24, and 25 (p<0.05). IPSS decreased from 16.5 preoperatively to 10, 6, 7, and 7.5 (p<0.05; Table 2). No significant differences were noted in PVR, IIEF, MSHQ-EjD, or SF-12. CONCLUSIONS: Catheter-free WVTT is feasible and improved voiding parameters and symptom scores. No changes in sexual function, infectious complications, or readmission were noted. Only 1 patient (5%) required postoperative catheterization within the first 30 days. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e429 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Vi Nguyen More articles by this author Joshua Winograd More articles by this author Alia J. Codelia-Anjum More articles by this author Kevin C. Zorn More articles by this author Dean Elterman More articles by this author Naeem Bhojani More articles by this author Seth K. Bechis More articles by this author Bilal Chughtai More articles by this author Expand All Advertisement PDF downloadLoading ...